Avenzo Therapeutics to present first ORION-1 Phase 1 data for selective CDK4 inhibitor AVZO-023
Avenzo will present first ORION-1 data for AVZO-023 in December, testing whether selective CDK4 inhibition offers a better tolerability profile.
Pharma & Biotech
Medical Devices & Diagnostics
How AidaBreast’s multi-omic insights may reduce overtreatment in breast cancer care
Prelude Corporation has announced the first independent validation of AidaBreast, a multi-omic diagnostic test developed to predict both locoregional recurrence risk and individualized radiation therapy benefit in early-stage hormone receptor-positive, HER2-negative invasive breast cancer. The study, conducted at Royal Melbourne Hospital and presented at the San Antonio Breast Cancer Symposium 2025, evaluated over 400 women